Aimmune Therapeutics’ (AIMT) Outperform Rating Reiterated at Wedbush

Wedbush reaffirmed their outperform rating on shares of Aimmune Therapeutics (NASDAQ:AIMT) in a research note issued to investors on Friday. They currently have a $70.00 price objective on the biotechnology company’s stock.

A number of other research firms also recently issued reports on AIMT. Roth Capital assumed coverage on Aimmune Therapeutics in a research note on Monday, November 20th. They set a buy rating and a $60.00 price target for the company. Zacks Investment Research upgraded Aimmune Therapeutics from a hold rating to a buy rating and set a $34.00 price target for the company in a research note on Wednesday, November 8th. Credit Suisse Group boosted their price target on Aimmune Therapeutics from $36.00 to $45.00 and gave the company an outperform rating in a research note on Monday, October 23rd. Piper Jaffray Companies set a $38.00 price objective on Aimmune Therapeutics and gave the company a buy rating in a research note on Saturday, October 21st. Finally, BidaskClub downgraded Aimmune Therapeutics from a hold rating to a sell rating in a research note on Friday, August 11th. Two investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $49.40.

Aimmune Therapeutics (AIMT) opened at $38.02 on Friday. Aimmune Therapeutics has a 52-week low of $15.97 and a 52-week high of $38.86.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.09. equities research analysts predict that Aimmune Therapeutics will post -2.57 EPS for the current fiscal year.

In other news, insider Douglas T. Sheehy sold 47,425 shares of the company’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $34.44, for a total transaction of $1,633,317.00. Following the sale, the insider now directly owns 34,300 shares of the company’s stock, valued at approximately $1,181,292. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Douglas T. Sheehy sold 1,905 shares of the company’s stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $33.00, for a total value of $62,865.00. Following the sale, the insider now directly owns 1,905 shares in the company, valued at $62,865. The disclosure for this sale can be found here. Over the last three months, insiders sold 317,720 shares of company stock worth $8,400,244. 17.59% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of AIMT. Vanguard Group Inc. raised its holdings in Aimmune Therapeutics by 12.6% during the 2nd quarter. Vanguard Group Inc. now owns 2,476,836 shares of the biotechnology company’s stock valued at $50,923,000 after buying an additional 276,978 shares during the period. Eagle Asset Management Inc. raised its holdings in Aimmune Therapeutics by 6.3% during the 2nd quarter. Eagle Asset Management Inc. now owns 2,270,160 shares of the biotechnology company’s stock valued at $46,674,000 after buying an additional 135,374 shares during the period. Palo Alto Investors LLC raised its holdings in Aimmune Therapeutics by 9.9% during the 2nd quarter. Palo Alto Investors LLC now owns 1,289,719 shares of the biotechnology company’s stock valued at $26,517,000 after buying an additional 116,221 shares during the period. Point72 Asset Management L.P. raised its holdings in Aimmune Therapeutics by 10.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,098,087 shares of the biotechnology company’s stock valued at $27,222,000 after buying an additional 101,855 shares during the period. Finally, State Street Corp raised its holdings in Aimmune Therapeutics by 26.6% during the 2nd quarter. State Street Corp now owns 1,087,320 shares of the biotechnology company’s stock valued at $22,351,000 after buying an additional 228,429 shares during the period. 73.34% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This story was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.com-unik.info/2017/12/04/aimmune-therapeutics-aimt-outperform-rating-reiterated-at-wedbush.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

What are top analysts saying about Aimmune Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aimmune Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit